GENTRONIX Signs First Japanese Contracted Screening Collaboration with Kowa
MANCHESTER, England--(BUSINESS WIRE)--Sep 5, 2012 - Gentronix Ltd. today announced the company's first contracted screening project in Japan, with a major Japanese pharmaceutical manufacturer, Kowa Company, Ltd.
Under the agreement, Gentronix will conduct genotoxicity screening of compounds for Kowa for use in selected undisclosed therapeutic products in its development pipeline. Currently over 100 pharmaceutical and fine chemical companies in 17 countries have used the Gentronix proprietary GreenScreen HC assay technology as part of their genotoxicity profiling strategy.
“Gentronix is delighted to be working with Kowa in the Japanese market. We believe that the Gentronix GreenScreen assay with its outstanding specificity, high sensitivity and low compound requirement, is an ideal assay, as an early screen, to assist medicinal chemists make high quality compound decisions, improve attrition rates and avoid the late stage failure of drug candidates.” (John Nicholson, Gentronix CEO)
Gentronix Ltd. is a Manchester University spin-out company that provides services and solutions that help companies optimize the development of drugs and other chemicals, by reducing rates of attrition due to toxicity and ensuring safer products across a wide range of chemistry driven industries. The primary focus is on providing better hazard identification assays for genotoxicity through the use of patented human cell GADD45a reporter assays GreenScreen HC ™ and BlueScreen HC™. Gentronix provides screening kits and contract genotoxicity screening services for these assays in addition to related assays including Ames MPF, Micronucleus and Comet tests, as well as a wide range of ADME and predictive toxicity endpoints. For more information, see http://www.gentronix.co.uk/, or email us at email@example.com.
Kowa Company, Ltd. (KCL) is a privately held multinational company headquartered in Nagoya, Japan. Established in 1894, KCL is actively engaged in various manufacturing and commercial activities in many sectors, including pharmaceuticals, life sciences, information technology, textiles, machinery and various consumer products. KCL's pharmaceutical division was founded in 1947, and is focused on cardiovascular therapeutics, with Japan domestic sales of the company's flagship product, pitavastatin (known as LIVALO, LIVAZO and ALIPZA in different markets) totaling JP¥50 billion (approximately US$630 million) for 2011.
Additional information about Kowa Company Ltd. is available through its English corporate website at http://www.kowa.co.jp/eng/index.htm.
Contact: Gentronix Limited
For further information:
Dr. Steve Beasley, Commercial Director
Tel: +44 (0)161 603 7676
For further press information:
Dr. Catherine Butcher, or Nicola Aldren
Tel: +44 (0)161 925 4700
Fax: +44 (0)161 925 4701
Email: firstname.lastname@example.org, email@example.com
Posted: September 2012